This inspection is the fourth major regulatory inspection (after Russia, Canada and Brazil), cleared by this site in the past two years
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
First approved therapeutic regimen that combines an anti-PD-1 and an antibody-drug conjugate in the US in these patients
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
This combination has the potential to be the first treatment option combining an antibody-drug conjugate plus an immunotherapy in this treatment setting
ADCelerate delivers Phase I appropriate antibody-drug conjugate (ADC) drug substance and drug product for Investigational New Drug (IND) submission
Results demonstrated a 64.5% confirmed objective response rate in patients treated with investigational combination of enfortumab vedotin and pembrolizumab
Aurobindo Pharma Foundation endeavours to make a positive contribution to the underprivileged ommunities by supporting a wide range of socio-economic, educational, and health initiatives.
Gilman will be responsible for all business development and portfolio strategy efforts globally.
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Subscribe To Our Newsletter & Stay Updated
